Mechanisms of Oestrogen Receptor (ER) Gene Regulation in Breast Cancer

Overview

Journal Eur J Endocrinol

Publisher Oxford University Press

Specialty Endocrinology

Date 2016 Feb 18

PMID 26884552

Citations 49

Authors

J S Carroll

Affiliations

Soon will be listed here.

Abstract

Most breast cancers are driven by a transcription factor called oestrogen receptor (ER). Understanding the mechanisms of ER activity in breast cancer has been a major research interest and recent genomic advances have revealed extraordinary insights into how ER mediates gene transcription and what occurs during endocrine resistance. This review discusses our current understanding on ER activity, with an emphasis on several evolving, but important areas of ER biology.

Citing Articles

Roles of Post-Translational Modifications of Transcription Factors Involved in Breast Cancer Hypoxia.

Seymour L, Nuru N, Johnson K, Gutierrez J, Njoku V, Darie C Molecules. 2025; 30(3).

PMID: 39942749 PMC: 11820228. DOI: 10.3390/molecules30030645.

Isoform-level analyses of 6 cancers uncover extensive genetic risk mechanisms undetected at the gene-level.

Chang Y, Head S, Harrison T, Yu Y, Huff C, Pasaniuc B medRxiv. 2024; .

PMID: 39574839 PMC: 11581093. DOI: 10.1101/2024.10.29.24316388.

Prognostic significance of ER-to-PR difference in ER+/HER2- early breast cancer.

Wu X, Zhang W, Lu X, Zhong X, Bu H Sci Rep. 2024; 14(1):24431.

PMID: 39424816 PMC: 11489460. DOI: 10.1038/s41598-024-74608-w.

ERRα and ERRγ coordinate expression of genes associated with Alzheimer's disease, inhibiting to suppress tau phosphorylation.

Sato K, Takayama K, Saito Y, Inoue S Proc Natl Acad Sci U S A. 2024; 121(37):e2406854121.

PMID: 39231208 PMC: 11406303. DOI: 10.1073/pnas.2406854121.

Conserved role of FOXC1 in TNBC is parallel to FOXA1 in ER+ breast cancer.

Ramachandran R, Ibragimova S, Woods L, AlHouqani T, Gomez R, Simeoni F iScience. 2024; 27(8):110500.

PMID: 39171293 PMC: 11338131. DOI: 10.1016/j.isci.2024.110500.

References

Carroll J, Meyer C, Song J, Li W, Geistlinger T, Eeckhoute J . Genome-wide analysis of estrogen receptor binding sites. Nat Genet. 2006; 38(11):1289-97. DOI: 10.1038/ng1901. View

VAN GILSE H, Hop W, Phoa C, Treurniet R . Progestin therapy in advanced breast cancer: megestrol acetate--an evaluation of 160 treated cases. Cancer. 1980; 46(11):2369-72. DOI: 10.1002/1097-0142(19801201)46:11<2369::aid-cncr2820461111>3.0.co;2-3. View

Peters A, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera M, Harris J . Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res. 2009; 69(15):6131-40. DOI: 10.1158/0008-5472.CAN-09-0452. View

Hickey T, Robinson J, Carroll J, Tilley W . Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?. Mol Endocrinol. 2012; 26(8):1252-67. PMC: 3404296. DOI: 10.1210/me.2012-1107. View

Kong S, Li G, Loh S, Sung W, Liu E . Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state. Mol Syst Biol. 2011; 7:526. PMC: 3202798. DOI: 10.1038/msb.2011.59. View

Smid M, Wang Y, Klijn J, Sieuwerts A, Zhang Y, Atkins D . Genes associated with breast cancer metastatic to bone. J Clin Oncol. 2006; 24(15):2261-7. DOI: 10.1200/JCO.2005.03.8802. View

Berry M, Nunez A, Chambon P . Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. Proc Natl Acad Sci U S A. 1989; 86(4):1218-22. PMC: 286657. DOI: 10.1073/pnas.86.4.1218. View

Ingle J, Ahmann D, Green S, Edmonson J, Creagan E, Hahn R . Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am J Clin Oncol. 1982; 5(2):155-60. DOI: 10.1097/00000421-198204000-00062. View

Daniel A, Gaviglio A, Knutson T, Ostrander J, DAssoro A, Ravindranathan P . Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. Oncogene. 2014; 34(4):506-15. PMC: 4112172. DOI: 10.1038/onc.2013.579. View

10.

Fisher B, Costantino J, Wickerham D, Cecchini R, Cronin W, Robidoux A . Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005; 97(22):1652-62. DOI: 10.1093/jnci/dji372. View

11.

Theodorou V, Stark R, Menon S, Carroll J . GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. Genome Res. 2012; 23(1):12-22. PMC: 3530671. DOI: 10.1101/gr.139469.112. View

12.

Brisken C, Ataca D . Endocrine hormones and local signals during the development of the mouse mammary gland. Wiley Interdiscip Rev Dev Biol. 2015; 4(3):181-95. DOI: 10.1002/wdev.172. View

13.

Mohammed H, Russell I, Stark R, Rueda O, Hickey T, Tarulli G . Progesterone receptor modulates ERα action in breast cancer. Nature. 2015; 523(7560):313-7. PMC: 4650274. DOI: 10.1038/nature14583. View

14.

Toy W, Shen Y, Won H, Green B, Sakr R, Will M . ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013; 45(12):1439-45. PMC: 3903423. DOI: 10.1038/ng.2822. View

15.

Zwart W, Theodorou V, Kok M, Canisius S, Linn S, Carroll J . Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancer. EMBO J. 2011; 30(23):4764-76. PMC: 3243612. DOI: 10.1038/emboj.2011.368. View

16.

Klinge C . Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 2001; 29(14):2905-19. PMC: 55815. DOI: 10.1093/nar/29.14.2905. View

17.

Tan S, Lin Z, Chang C, Varang V, Chng K, Pan Y . AP-2γ regulates oestrogen receptor-mediated long-range chromatin interaction and gene transcription. EMBO J. 2011; 30(13):2569-81. PMC: 3155293. DOI: 10.1038/emboj.2011.151. View

18.

Eeckhoute J, Keeton E, Lupien M, Krum S, Carroll J, Brown M . Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res. 2007; 67(13):6477-83. DOI: 10.1158/0008-5472.CAN-07-0746. View

19.

IZUO M, Iino Y, Endo K . Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer. A preliminary report of clinical and experimental studies. Breast Cancer Res Treat. 1981; 1(2):125-30. DOI: 10.1007/BF01805865. View

20.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View